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CObjective: To assess the cost-effectiveness of eplerenone versus spi-
ronolactone as an adjunctive therapy to standard care in patients with
heart failure (HF) following a myocardial infarction (post-MI) from the
perspective of the National Health Service in the United Kingdom.
Methods: A systematic review was conducted, and a Bayesian meta-
regression approach was used to establish the relative effectiveness of
eplerenone and spironolactone by using evidence from randomized
controlled trials. A decision analyticmodelwas developed to assess the
costs and consequences associated with the primary outcome of the
trials over a lifetime time horizon. Results: The incremental cost-effec-
tiveness ratio of eplerenone compared with that of standard care alone
was £4457 and £7893 for each additional quality-adjusted life-year when
2-year and lifetime treatment duration was assumed, respectively. In
both scenarios, spironolactone did not appear cost-effective compared
with eplerenone. The results were sensitive to the higher relative effec-
tiveness estimated for eplerenone compared with spironolactone from O
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oi:10.1016/j.jval.2012.01.004he meta-regression. When a class effect was assumed for the effect on
ortality and hospitalizations, spironolactone emerged as themost cost-
ffective treatment.Conclusions: Eplerenone appearsmore cost-effec-
ive than spironolactone for the treatment of post-MI HF. These find-
ngs, however, remain subject to important uncertainties regarding the
ffects of treatment on major clinical events. An adequately powered,
ell-conducted randomized controlled trial that directly compares spi-
onolactone and eplerenone may be required to provide more robust
vidence on the optimal management of post-MI HF. Despite these
ncertainties, the use of an aldosterone antagonist was consistently
emonstrated to be a highly cost-effective strategy for the manage-
ent of post-MI HF in the National Health Service.
eywords: cardiovascular diseases, cost-effectiveness analysis, epler-
none, spironolactone.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Heart failure (HF) is a syndrome of symptoms of breathlessness
or fatigue in the presence of cardiac dysfunction. The most
common cause of HF is ischemic heart disease, which fre-
quently presents acutely as myocardial infarction (MI). If large
volumes of cardiac muscle are damaged at the index event, HF
can present during the same admission (post-MI HF). Despite, or
as a consequence of, improved access to reperfusion strategies
(thrombolysis or percutaneous angioplasty) with the conse-
quent improved survival and the shifting age distribution of the
population, the incidence of post-MI HF is increasing in the
United Kingdom [1,2]1. The number of people with post-MI HF in
the United Kingdom for the year 2000 was estimated to be be-
tween 130,000 and 202,000, with associated annual costs to the
National Health Service (NHS) in the region of £125 million to
£181 million [3].
Following an ischemic event, cardiac and vascular adaptation oc-
curs with the aim of compensating for the loss of heart muscle. This
* Address correspondence to: Claire McKenna, Centre for Health E
DD, UK.
E-mail: claire.mckenna@york.ac.uk.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.adaptation, which involves the activation of multiple neurohor-
monal pathways, including aldosterone, leads tomyocardial fibrosis,
regionalmyocardial hypertrophy (knownas remodeling), and vascu-
lar vasoconstriction and eventually contributes to the ongoing dete-
rioration in cardiac function and worsening of the HF syndrome.
The aldosterone antagonist spironolactone reduces morbidity
and mortality in severe chronic HF (at least 3 months following an
cute coronary syndrome) [4,5], but it has not been tested in acute
ostinfarct HF. On the other hand, eplerenone, a more selective
ldosterone antagonist, is of benefit in patients presenting with
igns or symptoms of HF immediately during an index admission
ith an acute MI but follow-up was limited to 1 year following the
ndex event [6]. A third aldosterone anatagonist canrenone, which
s the activemetabolite of spironolactone and potassium canreno-
te, is not currently licensed as a human medicine in the United
ingdom.
Clinical guidelines reflect the randomized studies from which
hey are drawn and advocate the use of eplerenone for the man-
gement of post-MI HF and spironolactone for themanagement of
mics, Alcuin “A” Block, University of York, Heslington, York YO10
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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uate the relative cost-effectiveness of the two currently available
aldosterone antagonists in a post-MI HF population. As a result of
its higher selectivity, eplerenonemight bemore clinically effective
and better tolerated than spironolactone, but the latter has lower
acquisition costs. A recent pharmacoeconomic review of epler-
enone concluded that a direct comparison of the treatments
would be of interest [7]. In the absence of direct evidence from a
“head-to-head” randomized controlled trial (RCT) comparing the
alternative aldosterone antagonists, our aim was to develop a
cost-effectivenessmodel to formally assess and compare the cost-
effectiveness of eplerenone versus spironolactone specifically for
the management of post-MI HF from the perspective of the UK
NHS by using indirect methods [8]. Value of information analysis
was used to assist in establishing the potential value of a future
head-to-head trial of spironolactone and eplerenone and to in-
form future research priorities [9].
Methods
Overview
A probabilistic decision analytic model was developed to assess
the cost-effectiveness of eplerenone versus spironolactone as
an adjunctive therapy to standard care in patients with post-MI
HF. The model evaluated a population of patients who were
characteristic of patients in the Epleronone Post-Acute Myocar-
dial Infarction Heart Failure Efficacy and Survival Study (EPHE-
SUS) [10].
The model structure and its underlying assumptions were de-
veloped in discussion with two UK clinical advisors with experi-
ence in clinical trials design and health economic modeling. In
developing themodel, there were two issues considered central to
the methods employed: 1) the need to consider evidence on the
clinical effectiveness of aldosterone antagonists in different HF
populations to make an indirect comparison of treatment effec-
tiveness for eplerenone and spironolactone and (2) the require-
ment to extrapolate outcomes beyond the time horizon of RCTs to
ensure that differences between treatments were appropriately
quantified in terms of their impact on lifetime costs and outcomes.
The analysis was conducted from the perspective of the NHS
and Personal Social Services, with costs expressed in 2008-2009
prices and health outcomes in quality-adjusted life-years (QALYs).
Costs and outcomes were discounted at 3.5% per year [11].
Model structure
The decision model comprised two components: a short-term el-
ement and a long-term Markov model. The short-term element
captured the initial 3-month period following an acute MI, while
the long-termMarkovmodel examined the progression of post-MI
HF over a patient’s remaining lifetime by using annual cycles. The
primary outcomes of interest were all-cause mortality and hospi-
talizations for cardiovascular (CV) causes. The CV events consid-
ered were acute MI, HF, stroke, ventricular arrhythmia, and mor-
tality.
Five health stateswere defined in theMarkovmodel: 1) post-MI
HF, 2) first year post-CV event, 3) subsequent year’s post-CV event,
4) CV death, and 5) non-CV death (not shown in Figure 1). Patients
who did not experience any events in the first 3 months following
the initial acute MI entered the Markov model in the post-MI HF
state, where they remained until they experienced a CV event or
death. Patients who experienced a nonfatal CV event in the first 3
months after the initial acute MI entered the Markov model in the
first year post-CV event state. These patients remained in this
state for 1 year, after which, they could experience another non-
fatal CV event and re-enter the first year post-CV event state, haveno additional events and enter the subsequent year’s post-CV
event state, or die. The period after a nonfatal CV event was sep-
arated into first year post-CV event and subsequent year’s post-CV
event to reflect the elevated risk of a further event within the year
after the first event. Patients who experienced a fatal event in the
short-term period or longer term exited the model.
The proportion of patients in each health state differed accord-
ing to the treatment received and was based on the relative effec-
tiveness of eplerenone and spironolactone.
Model inputs
Treatment effectiveness
A comprehensive systematic review and meta-analysis of the ef-
fects of aldosterone antagonists on all-cause mortality and hospi-
talizations for CV causes was undertaken following searches
across 18 electronic databases. The reviewwas supplemented by a
recent systematic review by Ezekowitz andMcAlister [12] examin-
ing the effects of aldosterone antagonists (including canrenoate)
in patients with post-MI HF and general HF. A full technical report
of this review has also been published [13].
No direct head-to-head trials comparing eplerenone with spi-
ronolactone in post-MI HF were found. The effect of eplerenone or
spironolactone, as an adjunctive therapy to standard care, was
evaluated in RCTswith standard therapy as a control. The primary
outcome reported across the trials was all-causemortality. Table 1
summarizes the evidence on all-cause mortality in different HF
populations. Only two of the trials were large RCTs; one examined
the effectiveness of eplerenone in patients with HF within 3 to 14
days of an acute MI (EPHESUS [10]), while the other examined the
effectiveness of spironolactone in patients with HF (RALES, Ran-
domized Aldactone Evaluation Study [21]).
The evidence from the full set of trials listed in Table 1 was
used to facilitate an indirect comparison of eplerenone and spi-
ronolactone by examining the relationships that exist between the
different treatments and the size of the treatment effect in the two
study populations (post-MI HF and general HF). A Bayesian meta-
regression approach that took the following form was used:
Log(RR)  0  1MI  2EPL  3CAN
whereMI is an indicator variable for population (1 for post-MIHF and
0 for general HF) and EPL and CAN are indicator variables for treat-
ment with eplerenone and canrenoate, respectively (0 for treatment
with spironolactone). The coefficient  estimated the relative treat-
Equation 3: Non-fatal 
CV event < 1 year
Post-MI HF
1st year post-
CV event
Subsequent years 
post-CV event
Dead
(CV causes)
Equation 2: Time to 
non-fatal CV event
Equation 1: Time to 
fatal CV event
Equation 4: Fatal 
CV event < 1 year
Equation 5: Time to 
non-fatal CV event 
> 1 year
Equation 6: Time to 
fatal CV event > 1 year
Fig. 1 – Structure of the long-term Markov model. CV,
cardiovascular; HF, heart failure; MI, myocardial infarction.0
ment effect of spironolactone comparedwith standard care in a gen-
e Effi
422 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 2 0 – 4 2 8eral HF population. The coefficient 1 estimated the increment in
relative risk for a post-MI HF population compared with the general
HF population. The coefficients 2 and 3 estimated the increment in
relative risk for treatment with eplerenone and canrenoate, respec-
tively, compared with spironolactone.
The approach allowed treatment-specific estimates to bemod-
eled in each population by drawing strength from the network of
evidence available and assuming that all treatments shared a sim-
ilar reduction/improvement in efficacy in one population com-
pared with another. The pooled relative risks with 95% credibility
intervals for spironolactone and eplerenone compared with stan-
dard care in post-MI HF are reported in Table 1. The estimate for
eplerenone was consistent with the findings of EPHESUS, while
the estimate for spironolactone was more uncertain based on the
more limited evidence available.
A secondary outcome of hospitalizations for CV causes was not
reported consistently across the trials. Therefore, meta-analytic ap-
proaches could not be used to derive a relativemeasure of treatment
effect for eplerenone compared with spironolactone for this out-
come. The relative risk of hospitalization for CV events for epler-
enone compared with standard care was informed by EPHESUS
(Table 2). We assumed that the same increment in relative risk be-
tween eplerenone and spironolactone observed for mortality could
be applied to the relative risk of hospitalizations for eplerenone to
obtainanestimateof the relative effectivenessofhospitalizations for
spironolactone compared with eplerenone.
Baseline event rates
The RCTs undertaken to evaluate the clinical effectiveness of epler-
enone and spironolactone were mainly or wholly undertaken out-
side the United Kingdom. In many respects, treatment patterns and
resource use in the United Kingdom can be expected to differ from
those in centers involved in the trials. One implication of this UK-
specific practice is that the baseline event rates observed in the con-
trol group of the trials are unlikely to provide reliable estimates for
UK practice. In addition, the limited follow-up reported in both
Table 1 – Summary of evidence on all-cause mortality.
Study Treatment Population
fo
Agostoni et al. [14] Spironolactone General HF
Akbulut et al. [15] Spironolactone General HF
Berry et al. [16] Spironolactone General HF
Chan et al. [17] Spironolactone General HF
Cicoira et al. [18] Spironolactone General HF
Gao et al. [19] Spironolactone General HF
Pitt [20] Spironolactone General HF
Pitt et al. [21]* Spironolactone General HF
Rodriguez et al. [22] Spironolactone Post-MI HF
Ruta et al. [23] Spironolactone Post-MI HF
Tsutamoto et al. [24] Spironolactone General HF
Tu and Chen [25] Spironolactone Post-MI HF
Pitt et al. [10]† Eplerenone Post-MI HF
Ezekowitz and McAlister [12] Eplerenone General HF
Boccanelli et al. [26] Canrenoate General HF
DiPasquale et al. [27] Canrenoate Post-MI HF
Modena et al. [28] Canrenoate Post-MI HF
Pooled estimate from
evidence synthesis
Eplerenone Post-MI HF
Spironolactone Post-MI HF
CI confidence interval; HF heart failure; MImyocardial infarctio
* Refers to Randomized Aldactone Evaluation Study.
† Refers to Epleronone Post-Acute Myocardial Infarction Heart FailurEPHESUS and RALES and the generalizability of RALES to a post-MIHF population raise additional issues regarding their suitability for
the purposes of long-term extrapolation.
Baseline event rates for mortality and hospitalizations for CV
causes for the first 3 months after an acute MI were derived by
using survival analysis methods based on rates observed in the
control arm of EPHESUS [10]. The EPHESUS population is immedi-
ately post-MI (up to 14 days) and at the start of HF development
(approximately 80% New York Heart Association class I or II). A
parametric Weibull distribution was fitted to data extracted from
the published Kaplan-Meier curve of the rate of death from any
cause to obtain an estimate of monthly transition probabilities for
all-cause mortality (Table 2). In the absence of a single Kaplan-
Meier curve reporting the rate of first hospitalization for a CV
event (a composite curve was reported for CV deaths or first CV
hospitalization), baseline hospitalization rates were derived from
data reported on the proportion of patients hospitalized over the
follow-up period. Over a mean follow-up of 16 months, 649 of the
3313 patients were hospitalized for a CV event [10], which equated
to a mean risk of 1.35% per month.
Central to the long-termmodelwas the subsequent event rates
for patients who survived the first 3 months after the MI. Extra-
polating the data from EPHESUS over a longer period appeared to
underestimate mortality in the long-term, with more than 50% of
patients predicted to be alive at 20 years post-MI based on the
predictions from the parametric survival analysis. Therefore, an
alternative source of baseline event rates for UKpractice providing
longer-term follow-up data was obtained from the linked Scottish
Morbidity Records [29]. Data from the Scottish Morbidity Records
were used to identify individuals at the start of HF development,
with data on MI as a comorbid diagnosis used to obtain estimates
for a post-MI HF cohort. Datawere obtained on all individuals with
a first discharge (no previous hospitalization for HF for aminimum
of 5 years before the index admission) from hospital between 1993
and 2003 with a principal diagnosis of HF (n 39,307) (International
Classification of Diseases, Ninth Revision, codes 9 425.4, 425.5, 425.9,
428.0, 428.1, 428.9, 402, International Statistical Classification of Dis-
n
-up
)
Treatment Standard care Trial-specific
estimates of RR
Dead Total Dead Total RR 95% CI
0 15 0 15 — —
0 35 0 70 — —
0 20 0 20 — —
0 23 0 25 — —
3 54 4 52 0.722 0.170–3.072
0 58 0 58 — —
0 174 0 40 — —
284 822 386 841 0.753 0.668–0.848
1 23 2 24 0.522 0.051–5.370
11 22 8 25 1.562 0.770–3.171
0 20 0 17 — —
1 43 7 42 0.140 0.018–1.086
478 3319 554 3313 0.861 0.770–0.964
1 114 1 38 0.333 0.021–5.201
6 231 12 236 0.511 0.195–1.338
22 341 32 346 0.698 0.414–1.175
0 24 2 22 0.184 0.009–3.634
0.861 0.767–0.964
1.020 0.575–1.652
 relative risk.
cacy and Survival Study.Mea
llow
(mo
6
3
3
12
12
6
3
24
6
4
16
3
12
6
12
n; RReases, 10th Revision, codes I50, I42.0, I42.6, I42.7, I42.9) [33]. For these
Im
423V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 2 0 – 4 2 8individuals, data were available on subsequent major CV events
(MI, stroke, angina, and otherHF events), aswell as deaths fromCV
and non-CV causes until December 2005. These data were used to
derive survival equations and logit models to predict time-to-
event or death based on a set of baseline characteristics.
The transition arrows between the health states in Figure 1 are
labeled with an equation number. These equations estimate the re-
lationship between the event and the individual’s characteristics to
facilitate the simulation of fatal and nonfatal events that a cohort of
patients would be expected to experience over the long term. Equa-
tions 1 and 2 predict the primary outcomes of a fatal andnonfatal CV
event, respectively. The risk is predicted on the basis of a set of base-
line characteristics of age, gender, medical history (comorbidities of
diabetes, atrial fibrillation, hypertension, angina, stroke, andMI) and
year of admission/diagnosis. Equations 3 and 4 relate to the proba-
bility that having had a nonfatal CV event, a subsequent event (non-
fatal and fatal, respectively) within 12 months of the first event oc-
curs. Equations 5 and 6 estimate the risk of a subsequent CV event
Table 2 – Summary of input parameters applied in the bas
Variables Val
Baseline patient characteristics
Age (y)
Sex 70% men
Relative treatment effect on all-cause mortality
Spironolactone 1.02
Eplerenone 0.86
Relative treatment effect on CV hospitalization
Spironolactone 1.00
Eplerenone 0.91
Baseline event rates in short-term model
All-cause mortality 4.73%, 1.81%
1–3, respec
CV hospitalization 1.35% per mo
Baseline event rates in long-term model
Time to fatal CV event
Time to nonfatal CV event
Nonfatal CV event 1 y 0.1
Fatal CV event 1 y 0.1
Time to nonfatal CV event 1 y
Time to fatal CV event 1 y
Proportion experiencing CV events
Acute MI 0.3
Heart failure 0.5
Stroke 0.0
Ventricular arrhythmia 0.0
Unit costs of CV events (£)
Acute MI 11
Heart failure 15
Stroke 20
Ventricular arrhythmia 7
Unit costs of aldosterone antagonists (£)
Spironolactone 3.86 per mon
Eplerenone 46.41 per mo
Utility decrements associated with health states
Baseline utility 0.75
0 rehospitalizations Reference gr
1 rehospitalizations 0.02
2 rehospitalizations 0.03
3 rehospitalizations 0.05
Annual discount rate (%)
On QALYs 3
On costs 3
CrI  credibility interval; CV cardiovascular; SE  standard error; M(nonfatal and fatal, respectively) after 12 months of the first event,where information on the primary event was used to update the
history of stroke, angina, and MI.
Although the Scottish Morbidity Records data were used to de-
rive the equations described above, the predicted risk of the events
was based on baseline characteristics and CV events observed in
the EPHESUS population, given that this population is representa-
tive of post-MI HF.
Risk of noncardiovascular mortality
The age-dependent risk of other-cause mortality was based on
standard UK age- and sex-specificmortality rates [34]. These rates
were adjusted to exclude those deaths pertaining to CV mortality
by using a cause elimination approach, according to standard
methods used by the Office for National Statistics [35].
Resource use and unit costs
A unit cost was attached to each nonfatal CV event that occurred
over time (Table 2). The proportion of patients experiencing
e model.
5% CrI) Distribution Study
Fixed [10]
Fixed [10]
75–1.652) Posterior of synthesis
67–0.964) Posterior of synthesis
97–1.008) Lognormal
10–1.010) Lognormal [10]
1.36% in months Weibull (  0.461,   0.048) [10]
Beta [10]
Weibull (  0.519,   0.008) [29]
Weibull (  0.643,   0.015) [29]
Exponential [29]
Exponential [29]
Weibull (  1.609,   0.000) [29]
Weibull (  1.618,   0.000) [29]
Dirichlet [10]
Dirichlet [10]
Dirichlet [10]
Dirichlet [10]
Fixed [30]
Fixed [30]
Fixed [30]
Fixed [30]
Fixed [31]
Fixed [31]
 0.040) Beta [32]
— [32]
 0.007) Gamma [32]
 0.009) Gamma [32]
 0.001) Gamma [32]
Fixed [11]
Fixed [11]
yocardial infarction; QALY quality-adjusted life-year.e-cas
ue (9
65
0 (0.5
1 (0.7
2 (0.9
0 (0.8
, and
tively
nth
42
89
16
39
70
75
43
38
81
54
th
nth
9 (SE
oup
4 (SE
1 (SE
5 (SE
.5
.5acute MI, HF, stroke, and ventricular arrhythmia was informed
f
e
a
£
s
p
w
t
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of Reference Costs for NHS trusts for 2007-2008 based on a
weighted average of short- and long-stay visits and number of
patients incurring complications associated with the event [30].
An annual background cost of HF (£462 per person per year)
relating to routine management was applied for the length of
time that a patient was alive within the model based on British
Heart Foundation statistics, which estimated that the annual
cost of HF to the NHS in 2000 was £628.6 million [36].
The costs of spironolactone and eplerenone were obtained
rom the British National Formulary [31]. The dosage of epler-
none was assumed to be 25 mg taken daily for the first 4 weeks
nd 50 mg thereafter. A 28-tablet pack of 50-mg strength costs
42.72, which results in an annual cost of £557. The dosage of
pironolactone was assumed to be 100 mg per diem. A 28-tablet
ack of 100-mg strength of generic spironolactone costs £3.55,
hich results in an annual cost of £46. All patients, regardless of
reatment strategy, were assumed to receive standard therapy.
Quality-of-life adjustment
To estimate QALYs, it was necessary to quality adjust the period of
time the average patient was alive within the model using an ap-
propriate utility or preference score. A recent study by Gohler et al.
[32] used primary data from EPHESUS, based on the EuroQol five-
dimensional questionnaire, to estimate utility values for patients
with HF according to number of rehospitalizations for CV causes.
This study was used to provide the underlying baseline utility for
post-MI HF and a utility decrement for each rehospitalization
(Table 2). To reflect the decreasing utility of patients as they age
through the model, age- and sex-adjusted norms for the United
Kingdom [37] were adjusted downward by approximately 5% to
reflect the existence of HF.
Analytical methods
Themodel was run probabilistically by using Monte Carlo simula-
tion, and the uncertainty in the parameters was characterized by
using the probability distributions summarized in Table 2. The
results are presented in two ways: First, mean lifetime costs and
QALYs for spironolactone, eplerenone, and standard care alone
are presented and their cost-effectiveness is compared by using
incremental cost-effectiveness ratios (ICERs) [38]. Second, decision
uncertainty is presented as the probability that each treatment is the
more cost-effective option for a given cost-effectiveness threshold.
This threshold represents the amount the NHS is prepared to pay to
gain one additionalQALY. TheNational Institute forHealth andClin-
ical Excellence currently uses a cost-effectiveness threshold range of
£20,000 to £30,000 per QALY gained. A distribution of the uncertainty
in the estimate of cost-effectiveness is reflected by using cost-effec-
tiveness acceptability curves [39].
The analyses were undertaken for a population in which the
average age was 65 years and 70% were males. In the base-case
analysis, treatment with aldosterone antagonists was assumed to
be given for a maximum of 2 years, consistent with the length of
follow-up of EPHESUS. A separate analysis was undertaken as-
suming lifetime treatment duration. Uncertainty surrounding the
evidence used to inform the efficacy of the aldosterone antago-
nists was explored in two scenarios. First, the impact of excluding
weaker studies from the synthesis was considered: 1) HF trials
with follow-up durations of less than 3 months and 2) low-quality
studies with few events reported in the arms of the trial. Second, a
class effect was consideredwhere it was assumed that eplerenone
and spironolactone had equal efficacy but differed in the rate of
gynecomastia, an adverse event associated with spironolactone
use. In this scenario, gynecomastia was assumed to reduce overall
compliance with spironolactone, with 10% of patients discontinu-
ing spironolactone treatment because of gynecomastia compared
with 0% of patients receiving eplerenone.Value of information analysis was used to quantify the cost
associated with the decision uncertainty related to the use of al-
dosterone antagonists for post-MI HF. The expected cost of uncer-
tainty surrounding the adoption decision is determined by the
expected value of perfect information (EVPI) [9,40,41]. The EVPI
provides an estimate of the value of completely resolving all ex-
isting uncertainty and provides a measure of the maximum re-
turns to further research. The value depends crucially on the num-
ber of future patients who could benefit from further research and
the time horizon over which the information would be useful.
Post-MI HF accounts for approximately 20% of all HF cases [42].
The British Heart Foundation estimates that the prevalence of HF
in the United Kingdom is 707,000 (393,000 men, 314,000 women)
and the annual incidence of HF is estimated to be 68,000 cases
(38,000 men, 30,000 women) [4]. Together these sources suggest a
prevalence of about 141,400 and an annual incidence of around
13,600 for post-MI HF. Assuming a 10-year time horizon for the
lifetime of the technologies being considered, this gives an effec-
tive population of 258,465 (prevalent and incident population per
annum discounted at 3.5% over the lifetime of the technology) for
the population EVPI analysis. EVPI is presented for the base-case
analysis and the alternative scenarios.
Results
Base-case analysis
Table 3 presents the base-case results for the treatment duration
of 2 years and lifetime. For the 2-year analysis, eplerenone appears
more cost-effective than either spironolactone or standard care
alone. Based on expected (mean) costs and QALYs, spironolactone
is less effective and more costly than standard care alone and is
therefore dominated by standard care. Eplerenone is expected to
result in a gain of 0.25 QALYs compared with standard care alone
at an additional cost of £1120. The ICER of eplerenone is £4457 per
QALY. At thresholds of £10,000, £20,000, and £30,000 per QALY, the
probability that eplerenone is more cost-effective than the other
treatments is 0.61, 0.66, and 0.68, respectively. The degree of deci-
sion uncertainty is illustrated in Figure 2, which presents the cost-
effectiveness acceptability curve for each strategy. At low values
of the threshold, standard care has the highest probability of being
cost-effective. As the threshold increases, however, uncertainty
surrounding cost-effectiveness is almost entirely between epler-
enone and spironolactone. This uncertainty translates into a very
high cost of decision uncertainty, as shown by the EVPI.
For the lifetime analysis, eplerenone also appears more cost-
effective than spironolactone or standard care. Eplerenone ismore
expensive than spironolactone, but it has a lower ICER. The ICER
of £7893 for eplerenone compared with standard care alone is
less favorable with lifetime treatment compared with 2-year
treatment but still remains well below conventional cost-effec-
tiveness thresholds considered to represent value for money in
the NHS. Higher decision uncertainty in the lifetime analysis is
reflected in higher EVPI. These estimates are between two and
three times higher than the comparable estimates reported for
a 2-year treatment duration.
Alternative scenarios
Table 4 presents the results of alternative scenarios for the treat-
ment duration of 2 years and lifetime. The results appear robust to
the exclusion of trials reporting follow-up durations of less than 3
months. Eplerenone consistently appears more cost-effective
than either spironolactone or standard care alone. In the lifetime
analysis, spironolactone has a lower ICER than does eplerenone
when compared with standard care, but the ICER of £8962 per
en pa
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low conventional cost-effectiveness thresholds.
When the evidence excludes low-quality small studies, spi-
ronolactone is no longer dominated by standard care alone in
either the 2-year or lifetime analyses. For the 2-year treatment
duration, the ICER of spironolactone is £532 per QALY when
compared with standard care, while the ICER of eplerenone
when compared with spironolactone is £1949 per QALY. For the
lifetime treatment duration, the ICER of spironolactone when
compared with standard care is £43 per QALY and the ICER of
eplerenone when compared with spironolactone is £4798 per
QALY. Therefore, although spironolactone is not dominated by
either standard care or eplerenone, the ICER of eplerenone
when compared with spironolactone demonstrates that epler-
enone remains the more cost-effective treatment based on con-
ventional thresholds.
The scenario where the aldosterone antagonists are assumed
to have the same efficacy, but a difference in overall compliance of
10%with spironolactone use comparedwith eplerenone use, has a
marked effect on the estimates of cost-effectiveness. In both the
2-year and lifetime analyses, the ICER of eplerenone when com-
pared with spironolactone increases above conventional thresh-
olds of cost-effectiveness (£44,134 and £70,509 per QALY for 2-year
and lifetime treatment durations, respectively). Despite the addi-
tional risk of discontinuation for spironolactone use, spironolac-
tone emerges as themore cost-effective treatment with an ICER of
£1046 and £1280 perQALY for 2-year and lifetime analyses, respec-
Table 3 – Results of base-case analysis of aldosterone anta
Treatment Mean QALYs Mean costs (£)
2-y treatment
Standard care (SC) 4.5972 4129
Spironolactone 4.5551 4191
Eplerenone 4.8486 5249
Population EVPI
Lifetime treatment
Standard care 4.5981 4130
Spironolactone 4.6196 4446
Eplerenone (Ep) 5.1108 8177
Population EVPI
D dominated (one or more alternative treatments are cheaper a
treatments are more expensive but have lower ICER); EVPI expec
cost-effectiveness ratio; MImyocardial infarction; QALY quality-a
* Probability that treatment is more cost-effective than all others giv
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Fig. 2 – Cost-effectiveness acceptability curve for the base-
case with 2-year treatment duration.tively, compared with standard care alone. Employing this sce-
nario also has a marked effect on the EVPI estimates. The proba-
bility that spironolactone is the most cost-effective strategy is
close to 1 across thresholds. This results in an EVPI of between
£176,000 and £1.8million, suggesting that a further trial under this
scenario would appear less valuable.
Discussion
Clinical guidelines reflect the evidence from clinical studies and
advocate the use of eplerenone for themanagement of post-MI HF
and the use of spironolactone for chronic HF. No previous studies,
however, have attempted to formally evaluate the relative cost-
effectiveness of eplerenone and spironolactone directly in a
post-MI HF population. The present study provides the first com-
parative assessment of the cost-effectiveness of the two currently
available aldosterone antagonists in patients with post-MI HF in
the UK NHS based on formal systematic reviewmethods and eco-
nomic modeling.
We have shown that eplerenone consistently emerges as a po-
tentially more cost-effective strategy than spironolactone for the
management of post-MI HF. The ICER for eplerenone falls below
the £20,000 to £30,000 per QALY threshold of cost-effectiveness
that is conventionally used to establish value for money in the
NHS. This is largely the result of greater clinical effectiveness of
eplerenone compared with spironolactone in terms of all-cause
mortality and hospitalizations for CV events estimated from the
indirect evidence synthesis. The population EVPI estimates sug-
gest that further research is likely to be of significant value, indi-
cating that a future head-to-head trial of the two treatments in a
post-MI HF population is highly valuable.
In the absence of a direct head-to-head RCT comparing
eplerenone and spironolactone and the inevitable uncertainty
inherent in the indirect evidence synthesis methods employed,
a scenario was considered where the aldosterone antagonists
were assumed to have the same treatment effect on major clin-
ical events but allowed for differences in their side-effect pro-
file. This scenario had an important effect on the cost-effective-
ness results, with spironolactone now appearing the more cost-
effective strategy. In this case, the EVPI results indicate that
undertaking further primary research would be unlikely to rep-
sts for post-MI HF.
ICER Probability cost-effective*
£10,000 £20,000 £30,000
— 0.013 0.004 0.002
D (SC) 0.375 0.338 0.322
£4457 0.612 0.658 0.676
£277 million £485 million £696 million
— 0.116 0.009 0.003
D (Ep) 0.441 0.366 0.346
£7,893 0.443 0.625 0.651
£820 million £1265 million £1748 million
ore effective); ED extended dominance (one or more alternative
alue of perfect information; HF heart failure; ICER incremental
ed life-year.
rticular maximum willingness to pay for additional QALY.goni
E
nd m
ted v
djustresent value for money.
Table 4 – Results of alternative scenarios of aldosterone antagonists for post-MI HF.
2-y treatment duration Lifetime treatment duration
ICER Probability cost-effective* ICER Probability cost-effective*
£10,000 £20,000 £30,000 £10,000 £20,000 £30,000
Network of evidence
(i) Excluding trials with 3 mo follow-up
Standard care (SC) — 0.019 0.004 0.002 — 0.122 0.011 0.005
Spironolactone D (SC) 0.419 0.384 0.367 £3,684 0.471 0.413 0.392
Eplerenone £4,489 0.562 0.612 0.631 £8,962 0.407 0.576 0.603
Population EVPI £314 million £555 million £800 million £917 million £1,441 million £2004 million
(ii) Excluding low-quality studies
Standard care — 0.020 0.008 0.006 — 0.132 0.019 0.007
Spironolactone £532 0.384 0.366 0.363 £43 0.411 0.381 0.368
Eplerenone £1,949 0.596 0.626 0.631 £4,798 0.457 0.600 0.625
Population EVPI £483 million £907 million £1334 million £1,377 million £2,415 million £3,486 million
Equal efficacy for aldosterone antagonists but 10% lower
compliance with spironolactone
Standard care — 0.001 0.001 0.001 — 0.000 0.000 0.000
Spironolactone £1,046 0.999 0.999 0.944 £1,280 1.000 1.000 1.000
Eplerenone £44,134 0.000 0.000 0.055 £70,509 0.000 0.000 0.000
Population EVPI £176,276 £330,064 £1.8 million £311,307 £536,661 £767,520
Ddominated (one ormore alternative treatments are cheaper andmore effective); EVPI expected value of perfect information; HFheart failure; ICER incremental cost-effectiveness ratio;MI
myocardial infarction; QALY quality-adjusted life-year.
* Probability that treatment is more cost-effective than all others given particular maximum willingness to pay for additional QALY.
426
V
A
L
U
E
IN
H
E
A
L
T
H
1
5
(2
0
1
2
)
4
2
0
–
4
2
8
427V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 2 0 – 4 2 8Limitations
While the cost-effectiveness model has attempted to address a
number of important evidence gaps concerning the use of aldoste-
rone antagonists for the management of post-MI HF, a number of
important limitations to the analysis should be noted. The
strength of the conclusions clearly depends on the validity of the
indirect evidence synthesis. There remain a number of difficulties
in making a reliable comparison between spironolactone and
eplerenone based on the evidence from the available trials. The
only good-quality evidence for aldosterone inhibitors in a post-MI
HF population comes from a trial of eplerenone (EPHESUS [10]),
while the only large good-quality trial of spironolactone is in a
general HF population (RALES [21]). A number of other smaller
trials of unknownquality in different HF populations are available.
The approach employed to synthesize the evidence requires the
trials to be exchangeable within, although not across, the HF and
post-MI HF populations. Given the relatively low number of stud-
ies and the small sample sizes for many of these studies, the sta-
tistical absence of heterogeneity within the separate populations
may not provide sufficient evidence to support the assumptions
employed. Furthermore, it should be emphasized that the existing
RCT evidence for spironolactone in a post-MI HF population is
extremely limited compared with that for eplerenone. While this
is reflected in the wider confidence intervals for the treatment
effect estimate applied to spironolactone, the lack of robust evi-
dence specifically in the post-MI HF population represents amajor
limitation in terms of informing current service provision in the
NHS. It should also be recognized that data on other key inputs
into the model were less well reported in the RCTs. In particular,
data on nonfatal events requiring hospitalizationwere reported in
only a few of the RCTs, which meant that it was not possible to
undertake a robust synthesis of this data directly. Instead it was
assumed that the relative difference between eplerenone and spi-
ronolactone estimated for all-cause mortality would also be simi-
lar for nonfatal events. Therewas also a lack of data on the adverse
events associated with the aldosterone antagonists. A scenario
was consideredwhere gynecomastiawas assumed to reduce over-
all compliance with spironolactone, with 10% of patients discon-
tinuing spironolactone compared with 0% of patients on epler-
enone. This scenario, however, assumed that any additional costs
or loss of QALYs associated with gynecomastia were marginal.
Although the EVPI analysis quantifies the decision uncertainty
predicted by themodel and provides themaximum value that can
be placed on additional research, it does not address the structural
or methodological uncertainty inherent in the set of model as-
sumptions or provide a sufficient condition for conducting re-
search [40]. The choice between using effectiveness estimates
froman indirect evidence synthesis and assuming equal effective-
ness between treatments remains uncertain. This uncertainty is
not parameterized or captured by the EVPI analysis. Furthermore,
to establish a sufficient condition for research, the amount of un-
certainty that is likely to be resolved would have to be assessed
against the cost of research. Future developments would establish
the efficiency and optimal design of a future RCT.
Conclusions
The present analysis suggests that eplerenone is potentially more
cost-effective than spironolactone for the treatment of post-MI
HF. These findings, however, remain subject to important uncer-
tainties regarding the effects of treatment on major clinical
events. An adequately powered, well-conducted RCT that directly
compares spironolactone and eplerenone may be required to pro-
videmore robust evidence on the optimalmanagement of post-MI
HF patients, which could be informed by expected value of infor-
mation analysis. Despite these uncertainties, the analyses consis-tently demonstrated that the use of an aldosterone antagonistwas
a highly cost-effective strategy for the management of post-MI HF
patients in the NHS.
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